Fundamental analysis FULC (Fulcrum Therapeutics Inc)

Updated on 06/05/2026

We analyzed Fulcrum Therapeutics stock against the 10 quality criteria of Lubin Investment. The company gets a quality score of 4/10, meaning low quality.

Sector: Pharmaceuticals. Listing: US. Current price: 6.92 USD.

Lubin scoring methodology

Fulcrum Therapeutics Inc (FULC)'s score is calculated automatically from 10 objective financial criteria, with no human intervention or opinion. Each criterion is validated (YES / PARTIAL / NO) based on thresholds drawn from the financial literature (Warren Buffett, Bettin-Mauboussin, Aswath Damodaran). The final score is the sum of validations.

The 10 quantitative criteria analyzed

1. Profitable: positive net margin
2. Growing revenue: revenue growing > 10%/year over 5 years
3. Growing earnings per share: FCF per share adjusted for stock-based compensation, > 10%/year over 5 years
4. Share count under control: stable or declining (net buybacks = value creation for shareholders)
5. Cash profitability: free cash flow margin > 10% of revenue
6. Expanding margins: operating margin widens over 5 years (operating leverage)
7. Return on invested capital: Bettin-Mauboussin Cash ROCE > 15% per year
8. Debt under control: net debt repayable in less than 3 years of free cash flow
9. Earnings converted to cash: free cash flow exceeds accounting net income
10. Net collection period: short or negative cash conversion cycle

Frequently asked questions

Is Fulcrum Therapeutics a quality stock?

Fulcrum Therapeutics gets a quality score of 4/10 (low quality), calculated over the 10 Lubin Investment criteria: profitability, revenue and free cash flow growth, share buybacks, margins, debt and return on capital.

How is Fulcrum Therapeutics's score calculated?

The score is the total of validated criteria (YES / PARTIAL / NO) using thresholds drawn from the financial literature (Warren Buffett, Mauboussin, Aswath Damodaran), automatically and with no human opinion.

Where to see Fulcrum Therapeutics's full analysis?

The full interactive analysis (10-criteria detail, history, P/FCF valuation, sector comparisons) is available at https://lubin-investment.com/analyse/FULC?lng=en.

Other stocks in the Pharmaceuticals sector

• Septerna (SEPN) — score 6/10, P/FCF 14.5×
• Bausch Health Companies (BHC) — score 5/10, P/FCF 3.5×
• Hoth Therapeutics (RKTO) — score 5/10
• Lexicon Pharmaceuticals (LXRX) — score 5/10, P/FCF 57.0×
• MBX Biosciences (MBX) — score 5/10

Go further

👉 See the full interactive analysis of FULC

Other resources : Detailed methodology · All stocks in the Pharmaceuticals sector · Stocks rated 10 out of 10 · Top quality companies · Lubin Investment pricing.